2024 Latin America Conference on Lung Cancer (LALCA) - Posters-PP01.72: Real-World Outcomes of First-Generation EGFR Tyrosine Kinase Inhibitors in Advanced Non-Small Cell Lung Cancer in Uruguay.

PP01.72: Real-World Outcomes of First-Generation EGFR Tyrosine Kinase Inhibitors in Advanced Non-Small Cell Lung Cancer in Uruguay.

Back to course

Pdf Summary

This study, conducted by Alejandro Pérez, MD, Mauricio Cuello, MD, and Clara Rodríguez, MD, examines real-world outcomes of first-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) like erlotinib and gefitinib in treating advanced non-small cell lung cancer (NSCLC) in Uruguay. With the support of the Fondo Nacional de Recursos (FNR), Uruguay provides universal access to these treatments, creating a unique environment to evaluate their real-world effectiveness outside of clinical trials.<br /><br />Patients with advanced or recurrent NSCLC harboring activating EGFR mutations were identified from the FNR database, which encompasses data from 2012 to 2022. A total of 212 patients were studied, with 161 receiving erlotinib and 51 treated with gefitinib. The analyses focused on overall survival (OS) and progression-free survival (PFS) using Kaplan–Meier methods.<br /><br />Baseline characteristics indicated a median age of 66 for the entire cohort, with a slight predominance of female patients (61%). The majority of patients were non-smokers (89%), and the most common EGFR mutation identified was found in exon 19 (59%).<br /><br />The study found that while overall survival and progression-free survival rates were slightly lower than those reported in clinical trials, they remained consistent with outcomes observed in Western populations treated with these first-generation EGFR TKIs. The results underline the importance of real-world data in shaping clinical practices and ensuring that treatment outcomes align closely with those seen in everyday medical settings.<br /><br />This investigation offers valuable insights into the effectiveness of erlotinib and gefitinib, reinforcing their role in managing advanced NSCLC in Uruguay's healthcare system.

Asset Subtitle

Alejandro Perez

Keywords

EGFR

tyrosine kinase inhibitors

NSCLC

erlotinib

gefitinib

Uruguay

real-world outcomes

Fondo Nacional de Recursos

overall survival

progression-free survival